Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test to replace the scope? new ratios may spot IBD flares

NCT ID NCT07788131

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study tests whether ratios of routine blood markers—like C-reactive protein-to-albumin and neutrophil-to-lymphocyte—can accurately tell if inflammatory bowel disease (IBD) is active or in remission. Adults with Crohn's disease or ulcerative colitis will have blood tests and clinical evaluations; those undergoing routine colonoscopy will also have endoscopic scores recorded. The goal is to see if these inexpensive, non-invasive markers could serve as a simpler monitoring tool than endoscopy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood-derived inflammatory biomarker ratios (CAR, PAR, NLR, FAR, Hb/CRP) measured from routine blood tests
What this could lead to
If accurate, these blood test ratios could offer a simple, non-invasive way to monitor IBD activity, reducing the need for frequent invasive endoscopies.
What could go wrong
This is a cross-sectional study, so it can only show correlation, not cause. The markers may not be accurate enough to replace endoscopy in all patients, and results may vary across different IBD subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with an established diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis) presenting to the Department of Gastroenterology and Hepatology and the Department of Clinical Pathology at Assiut University Hospital.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Established diagnosis of Crohn's disease or ulcerative colitis * Availability of adequate clinical information for disease activity assessment * For the endoscopic subgroup: colonoscopy performed as part of routine clinical care within the study window with an available endoscopic report and corresponding disease activity score Exclusion Criteria: * Acute systemic infection at the time of assessment * Active malignancy * Other active systemic inflammatory or autoimmune diseases likely to significantly influence inflammatory biomarkers * Significant hematological disease affecting hemoglobin, leukocyte, neutrophil, lymphocyte, or platelet counts * Severe renal or hepatic dysfunction likely to substantially influence albumin or inflammatory markers * Recent major surgery * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease Inflammatory bowel diseases Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.